ENTERA BIO LTD. Operating Lease, Liability, Current
ENTERA BIO LTD. (ENTX) had Operating Lease, Liability, Current of $199.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-07
- 2026-06-30: Operating Lease, Liability, Current $199.00K.
- 2026-03-31: Operating Lease, Liability, Current $185.00K.
- 2025-12-31: Operating Lease, Liability, Current $230.00K.
- 2025-09-30: Operating Lease, Liability, Current $170.00K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $199.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $185.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $230.00K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $170.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $194.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $169.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $170.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $162.00K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $155.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $153.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $134.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $131.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $140.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $48.00K 10-Q · filed 2023-05-05 |
| 2022-12-31 | $91.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $129.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $172.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $142.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $179.00K 10-K · filed 2023-03-31 |
| 2020-12-31 | $189.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |